Genetic code expansion (GCE) technology enables the site-specific incorporation of non-canonical amino acids (ncAAs) into proteins, thereby vastly expanding the structural and functional diversity of polypeptides beyond the constraints of the 20 canonical amino acids. ncAA-based in vitro translation leverages cell-free protein synthesis systems to achieve this incorporation, offering a highly controlled and flexible platform for protein engineering. As a pioneering biotechnology company and a leading provider of preclinical services, we integrate our proprietary, high-throughput GCEngine platform with advanced cell-free synthesis methodologies. We deliver end-to-end, robust solutions for ncAA incorporation, positioning ourselves as your essential partner for advancing cutting-edge research in therapeutic discovery, synthetic biology, and diagnostic development.
The evolution of synthetic biology demands tools that transcend the complexities and constraints of living cells. In vitro translation using CFPS systems has emerged as a critical modality, not only for rapid protein production but also as a foundational platform for discovery. By decoupling protein synthesis from cell viability, CFPS eliminates common hurdles such as ncAA toxicity, poor cell permeability, and metabolic instability of novel substrates. Integrating GCE into these systems involves the deployment of orthogonal translation machinery, specifically, engineered pairs of tRNAs and their cognate aminoacyl-tRNA synthetases (aaRS). These pairs are designed to function independently of the host's native translation apparatus, selectively charging the tRNA with the desired ncAA and incorporating it at a designated reassigned codon (typically the amber stop codon, TAG).
Fig.1 Schematic of cell-free CFPS system preparation and ncAA incorporation competitors. (Wu, Y., et al., 2020).
Advanced systems often employ engineered extracts with suppressed RF1 activity or utilize entirely reconstituted PURE (Protein Synthesis Using Recombinant Elements) systems, which offer maximal flexibility by excluding native tRNAs and aaRS entirely, thereby minimizing background and enhancing orthogonality. Consequently, in vitro translation serves not only as a robust production platform for ncAA-containing proteins but also as an essential discovery and validation tool for characterizing novel orthogonal pairs and ncAA substrates before their deployment in more complex cellular environments.
Experimental Control and Flexibility
The reaction parameter, including pH, temperature, redox potential, ionic strength, and substrate concentration, can be precisely tuned and dynamically altered. This control is crucial for optimizing protein folding, maximizing ncAA incorporation efficiency, and maintaining the stability of chemically sensitive ncAAs during synthesis.
Accessibility and Compatibility
The open nature of CFPS allows for the incorporation of ncAAs that are incompatible with living systems, such as those that are cytotoxic, non-cell-permeable, or rapidly metabolized. It also facilitates the use of expensive or isotopically labeled ncAAs without concerns about metabolic dilution or scrambling.
Rapid Protein Production and Screening
By bypassing cell culture, transformation, and lysis steps, the process from DNA to protein can be completed in hours. This enables rapid parallel screening of protein variants, ncAAs, or orthogonal components, significantly accelerating the research and development design-build-test cycle.
Reduced Biological Complexity
The absence of intact cellular membranes, active metabolic networks, and native proteolytic systems minimizes confounding factors for mechanistic studies, enhances target protein yield by reducing degradation, and simplifies the purification and analysis of the modified product.
| Application Areas | Description |
| Bioconjugation and Protein Labeling | Enables site-specific introduction of bioorthogonal handles (e.g., azides, alkynes) for precise, homogeneous conjugation to fluorophores, polymers, toxins, or solid surfaces. |
| Structural Biology and Biophysics | Facilitates the incorporation of unique probes (e.g., NMR-active spins, heavy atoms for phasing, fluorescent amino acids for proximity-based fluorescence energy transfer measurements to study protein dynamics, interactions, and 3D structure. |
| Enzyme and Therapeutic Protein Engineering | Empowers novel function by installing ncAAs that confer new catalytic activity, modulate antibody effector functions, enhance stability (via D-amino acids, cross-linkers like diazirines), or lock therapeutic conformations for improved half-life and efficacy. |
| Basic Research in Translation | Serves as a fundamental tool for studying the mechanism and fidelity of protein synthesis, engineering aaRS/tRNA pairs, and exploring genetic code expansion in a controlled, cell-free environment. |
| Prototyping for In Vivo Systems | Provides an essential validation step for newly developed orthogonal aaRS/tRNA pairs and ncAA substrates before implementation in complex cellular or organismal systems. |
Powered by our proprietary, high-throughput GCEngine platform, we offer an end-to-end service suite for ncAA-based in vitro translation. Our expertise encompasses the identification and optimization of orthogonal aaRS/tRNA pairs tailored to your target ncAA, followed by rigorous validation in controlled cell-free systems. We provide tailored experimental designs to meet specific project goals, from initial proof-of-concept to production of modified proteins for functional characterization.
Powered by our proprietary GCEngine platform, we offer a comprehensive, collaborative service from concept to characterized protein.
Our approach leverages the flexibility of cell-free protein synthesis to bypass the limitations of in vivo toxicity and transport.
Bespoke Orthogonal Pair Development
High-throughput engineering of novel aaRS/tRNA pairs for client-supplied or novel ncAAs, including those designed for stability-enhancing incorporation.
Specialized CFPS System Setup
Adaptation of systems for non-standard requirements: oxidative folding for disulfide-rich proteins, integration of chaperones, or addition of detergents for membrane protein synthesis.
Multi-Site & Multi-ncAA Incorporation
Design and optimization for the simultaneous incorporation of two or more distinct ncAAs within a single polypeptide using multiple orthogonal pairs and codons, enabled by our reconstituted system expertise.
Integrated Applications
Combination of ncAA incorporation with subsequent on-site bioorthogonal labeling (e.g., click chemistry) or affinity tag introduction for immediate downstream applications.
High-Throughput Screening Support
Development of automated, microplate-based screening assays for libraries of protein variants, ncAA analogs, or engineered orthogonal machinery mutants.
By leveraging our specialized GCEngine platform and profound expertise in cell-free systems, we provide a powerful, reliable, and flexible pathway to access proteins engineered with non-canonical amino acids. Our comprehensive in vitro translation service is designed to de-risk and accelerate your research in synthetic biology, drug discovery, and advanced protein science, offering controlled, high-fidelity incorporation tailored to your precise requirements, including the critical goal of protein stabilization. To initiate a discussion on how we can partner to advance your next groundbreaking project, please contact our scientific services team.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.